CervoMed ownership: Morgan Stanley reports 8.0% stake

CervoMed Inc reports that Morgan Stanley entities hold an 8.0% beneficial ownership stake.

Rhea-AI Filing Summary

CervoMed Inc reports that Morgan Stanley entities hold an 8.0% beneficial ownership stake. The filing attributes shared voting power of 736,624 shares and shared dispositive power of 739,736 shares to Morgan Stanley reporting units. The filing is a joint Schedule 13G/A amendment signed by authorized Morgan Stanley representatives.

Insights

Institutional Ownership Analyst

Morgan Stanley-affiliated units report an 8.0% passive stake in CervoMed.

The Schedule 13G/A amendment lists shared voting power of 736,624 shares and shared dispositive power of 739,736 shares, reflecting holdings attributed to MS reporting units rather than a single individual.

Cash-flow treatment and acquisition timing are not disclosed in the excerpt; subsequent filings or exhibits may provide subsidiary identification and acquisition details.

Regulatory Compliance Specialist

The filing is presented under the Release that disaggregates Morgan Stanley operating units.

The amendment references Release No. 34-39538 and attaches Exhibit 99.2 for Item 7 subsidiary information. The joint filing structure and signatures indicate standard compliance rather than an active takeover or disposition.

Investors seeking entity-level attribution should consult Exhibit 99.2 and the joint filing agreement noted as Exhibit 99.1.

Key Figures

Percent of class: 8.0% Shared voting power: 736,624 shares Shared dispositive power: 739,736 shares

3 metrics

Percent of class 8.0% Beneficial ownership reported in Schedule 13G/A

Shared voting power 736,624 shares Reported shared voting power attributed to Morgan Stanley reporting units

Shared dispositive power 739,736 shares Reported shared dispositive power attributed to Morgan Stanley reporting units

Key Terms

Schedule 13G/A, MS Reporting Units, Shared Dispositive Power, Release No. 34-39538

4 terms

Schedule 13G/A regulatory

"This filing is an amendment to a Schedule 13G (13G/A)"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

MS Reporting Units financial

"securities beneficially owned by certain operating units (collectively, the "MS Reporting Units")"

Shared Dispositive Power regulatory

"Shared Dispositive Power 739,736.00"

Release No. 34-39538 regulatory

"In Accordance with the Release No. 34-39538 (January 12, 1998)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in CervoMed (CRVO) does Morgan Stanley report?

Morgan Stanley reports a 8.0% beneficial ownership stake in CervoMed. The amendment lists shared voting power of 736,624 shares and shared dispositive power of 739,736 shares attributed to MS reporting units.

Does the Schedule 13G/A show who within Morgan Stanley holds the shares?

The filing attributes holdings to MS reporting units and references Exhibit 99.2 for subsidiary identification. The amendment is a joint filing signed by Morgan Stanley authorized signatories indicating consolidated reporting.

Is this Schedule 13G/A an indication of active control or passive ownership?

Schedule 13G filings typically reflect passive or investment intent; this amendment lists shared powers and references the Release for reporting-unit aggregation, consistent with institutional reporting rather than an explicit control statement.

Are the acquisition date or transaction terms disclosed in this amendment?

The excerpt does not disclose acquisition dates or transaction terms. The filing includes exhibits (99.1 and 99.2) and signatures dated 05/11/2026 which may provide further detail.

Where can I find the detailed subsidiary attribution for these holdings?

The amendment references Exhibit 99.2 for Item 7 subsidiary information and Exhibit 99.1 for the joint filing agreement; those exhibits should identify the specific operating units and classifications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 01:41 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CervoMed Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

15713L109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 15713L109

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 736,624.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 739,736.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

739,736.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.0 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP Number(s): 15713L109

1

Names of Reporting Persons

Morgan Stanley Capital Services LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 736,624.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 736,624.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

736,624.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.0 %

12

Type of Reporting Person (See Instructions)

BD, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CervoMed Inc
(b)	Address of issuer's principal executive offices: 20 PARK PLAZA, SUITE 424, BOSTON, MA, 02116
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Capital Services LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 15713L109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 8.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	05/11/2026

Morgan Stanley Capital Services LLC

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley Capital Services LLC
Date:	05/11/2026

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).